Literature DB >> 18351467

Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease.

Dídia H Bismara Cury1, José Edson Costa, Kioshi Irika, Luciana Mijji, Alessandre Garcez, Carlos Buchiguel, Ivani Silva, Aytan Sipahi.   

Abstract

Indomethacin administration in animals increases permeability of the small intestine, leading to inflammation that mimics Crohn's disease. Nonsteroidal anti-inflammatory drugs increase the permeability of the intestinal epithelial barrier and should therefore be used with caution in patients with Crohn's disease. We analyzed the protective effects of octreotide and the tumor necrosis factor-alpha inhibitor infliximab in a rat model of indomethacin-induced enterocolitis. Male Wistar rats received 20 mg of infliximab or 10 mug of octreotide 24 h prior to injection with indomethacin. Intestinal permeability was analyzed using Cr-51-ethylenediaminetetraacetic acid clearance. No microscopic or macroscopic alterations were observed in the rats receiving infliximab or octreotide, both of which increased permeability (P < 0.001 versus controls). Our macroscopic and microscopic findings might be related to the low specificity of infliximab and suggest that cytokines affect the intestinal epithelial barrier, as evidenced by the protective effect that infliximab had on the permeability parameters evaluated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18351467     DOI: 10.1007/s10620-007-0172-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Clustering of increased small intestinal permeability in families with Crohn's disease.

Authors:  M Peeters; B Geypens; D Claus; H Nevens; Y Ghoos; G Verbeke; F Baert; S Vermeire; R Vlietinck; P Rutgeerts
Journal:  Gastroenterology       Date:  1997-09       Impact factor: 22.682

2.  Modulation of colonic barrier function by the composition of the commensal flora in the rat.

Authors:  A García-Lafuente; M Antolín; F Guarner; E Crespo; J R Malagelada
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 3.  Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

Authors:  R B Sartor
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

4.  Effects of octreotide treatment on early TNF-alpha production and localization in experimental chronic colitis.

Authors:  A Lamrani; M Tulliez; L Chauvelot-Moachon; S Chaussade; C Mauprivez; A M Hagnéré; N Vidon
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

5.  Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1).

Authors:  Jeroen D van Bergeijk; J H Paul Wilson; Ole Haage Nielsen; Christian von Tirpitz; Anna-Lusa Karvonen; I Lygren; Andreas Rädler; Helge L Waldum; Chris J J Mulder; S Friis; Solomon Tefera; Johannes F W Hoogkamer
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-03       Impact factor: 2.566

6.  Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo.

Authors:  C Högenauer; B Aichbichler; C Santa Ana; J Porter; J Fordtran
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

7.  Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.

Authors:  Carlos Felipe Bernardes-Silva; Adérson O M C Damião; Aytan M Sipahi; Francisco R M Laurindo; Kiyoshi Iriya; Fabio P Lopasso; Carlos A Buchpiguel; Maria Laura L Lordello; Carmem L O Agostinho; Antonio A Laudanna
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

8.  Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine.

Authors:  V Bertrand; R Guimbaud; M Tulliez; C Mauprivez; P Sogni; D Couturier; J P Giroud; S Chaussade; L Chauvelot-Moachon
Journal:  Br J Pharmacol       Date:  1998-08       Impact factor: 8.739

9.  Octreotide effectively decreases mucosal damage in experimental colitis.

Authors:  R Eliakim; F Karmeli; E Okon; D Rachmilewitz
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

10.  Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.

Authors:  Peter Suenaert; Veerle Bulteel; Liesbeth Lemmens; Maja Noman; Benny Geypens; Gert Van Assche; Karel Geboes; Jan L Ceuppens; Paul Rutgeerts
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  11 in total

1.  Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model.

Authors:  Lily Nahidi; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  J Gastroenterol       Date:  2011-09-28       Impact factor: 7.527

2.  Myosin light chain kinase inhibitor inhibits dextran sulfate sodium-induced colitis in mice.

Authors:  Xiaochang Liu; Jianming Xu; Qiao Mei; Liang Han; Jian Huang
Journal:  Dig Dis Sci       Date:  2012-07-10       Impact factor: 3.199

3.  Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.

Authors:  Sumanta Kumar Goswami; Amelia Ann Rand; Debin Wan; Jun Yang; Bora Inceoglu; Melany Thomas; Christophe Morisseau; Guang-Yu Yang; Bruce D Hammock
Journal:  Life Sci       Date:  2017-05-15       Impact factor: 5.037

4.  Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion.

Authors:  Ahmet Guzel; Mehmet Kanter; Aygul Guzel; Ahmet Pergel; Mustafa Erboga
Journal:  J Mol Histol       Date:  2012-03-03       Impact factor: 2.611

5.  Anti-Ulcer Efficacy of Soluble Epoxide Hydrolase Inhibitor TPPU on Diclofenac-Induced Intestinal Ulcers.

Authors:  Sumanta Kumar Goswami; Debin Wan; Jun Yang; Carlos A Trindade da Silva; Christophe Morisseau; Sean D Kodani; Guang-Yu Yang; Bora Inceoglu; Bruce D Hammock
Journal:  J Pharmacol Exp Ther       Date:  2016-03-17       Impact factor: 4.030

Review 6.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

7.  Effect of infliximab on acute hepatic ischemia/reperfusion injury in rats.

Authors:  Ahmet Fikret Yucel; Ahmet Pergel; Ibrahim Aydin; Hasan Alacam; Ilhan Karabicak; Tugrul Kesicioglu; Levent Tumkaya; Yildiray Kalkan; Ender Ozer; Zakir Arslan; Ibrahim Sehitoglu; Dursun Ali Sahin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 8.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

9.  Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management - a follow-up study in a private inflammatory bowel disease center (2003-2017).

Authors:  D B Cury; R Oliveira; M S Cury
Journal:  J Inflamm Res       Date:  2019-05-28

Review 10.  Effects of Anti-Cytokine Antibodies on Gut Barrier Function.

Authors:  Fang Liu; Seul A Lee; Stephen M Riordan; Li Zhang; Lixin Zhu
Journal:  Mediators Inflamm       Date:  2019-11-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.